All Insights

Standard growth-equity frameworks systematically misprice biotech risk — valuation here is driven by binary regulatory and clinical outcomes, not earnings or cash flow. A disciplined framework spanning vehicle selection (ETF, public stock, private/VC), five non-negotiable diligence dimensions, and the portfolio construction principle that no single trial outcome should be able to sink the whole position.

Comparing a biotech VC bet to a health services private equity deal under the single label "health care investing" is analytically misleading — each subsector demands its own framework, diligence method, and benchmark. Seven distinct risk profiles, mapped to public, private, and even career-equity pathways for exposure.

The highest-value health care opportunities sit at the intersection of technology, care coordination, and underserved populations — home-based care, mental health platforms, and AI-diagnostics carry the most durable structural tailwinds. A strategic map of the sector's core tensions and where each stakeholder group should focus.